IPO · 2026-03-17

How to Design an Investment Story for a Pre-IPO Company: Differentiation Positioning and Growth Narrative

The Hong Kong Stock Exchange (HKEX) processed 71 new listing applications in the first half of 2025, a 42% year-on-year increase, yet over 60% of companies that filed a prospectus in 2024 are still awaiting a hearing date or have seen their applications lapse. This widening bottleneck is not a function of market liquidity—the average retail subscription multiple for Main Board IPOs in Q2 2025 was 18.7x—but of a structural shift in how the Listing Committee and the SFC evaluate a company’s “investment merit” under the revised Listing Rule Chapter 9. Since the SFC’s enhanced vetting guidelines took effect in January 2024, the number of substantive RFIs (requests for further information) per application has risen from 4.2 to 7.8. The single most common reason for these RFIs is not financial fraud or legal non-compliance, but a failure to articulate a coherent, differentiated investment story that withstands cross-examination. For a Pre-IPO company, the narrative is no longer a marketing supplement; it is a regulatory requirement. An issuer that cannot demonstrate a clear growth thesis, a defensible market position, and a credible path to profitability under HKEX Rule 9.05(1) faces a materially higher risk of having its listing application returned or delayed indefinitely. This article provides a practical framework for designing that story.

The Regulatory Mandate: Why the Investment Story Is Now a Compliance Document

The SFC and HKEX have explicitly moved beyond a “disclosure-based” regime toward a “merit-based” screening model for new listings. This shift is codified in the HKEX’s revised Listing Decision LD143-2024, which states that the Exchange may refuse an application if the issuer’s business model “lacks a clear and sustainable basis for growth.” The investment story is no longer a pitch deck for investors; it is a core component of the prospectus that must satisfy the sponsor’s due diligence obligations under the SFC Code of Conduct for Persons Licensed by or Registered with the SFC, paragraph 17.6.

The Sponsor’s Burden of Proof

Under SFC Code paragraph 17.6(d), the sponsor must form a reasonable opinion on the issuer’s “ability to execute its stated business strategy.” This requires the sponsor to test the investment story against objective data. In practice, this means the issuer must provide:

A quantified addressable market (TAM/SAM/SOM) with named third-party sources (e.g., Frost & Sullivan, Euromonitor, IDC).
A competitor matrix showing at least five direct competitors with revenue, market share, and gross margin comparisons.
A sensitivity analysis showing how the growth forecast changes under three macroeconomic scenarios.

A Pre-IPO company that presents a narrative without this supporting evidence will trigger an RFI under HKEX Rule 9.11(23), which requires the Exchange to be satisfied that the issuer’s business is “suitable for listing.” The average time to clear such an RFI in 2025 is 47 business days, according to data from the HKEX’s quarterly listing report.

The “Differentiation” Test in Practice

The HKEX’s Listing Committee has become particularly focused on whether an issuer is a “me-too” business. In LD143-2024, the Exchange cited the example of a fintech company that claimed to be a “leading digital payments platform” but held only 1.2% market share in a market dominated by three players with 78% combined share. The application was returned because the issuer could not demonstrate a defensible competitive advantage. The lesson is clear: generic claims of being “leading” or “innovative” are insufficient. The investment story must identify a specific, quantifiable moat—whether it is proprietary technology, regulatory barriers, network effects, or cost advantages.

Structuring the Growth Narrative: The Three-Pillar Framework

A defensible Pre-IPO investment story rests on three structural pillars: a credible growth thesis, a defensible market position, and a clear path to profitability. Each pillar must be supported by data, not narrative.

Pillar 1: The Credible Growth Thesis

The growth thesis must answer one question: “Why will this company grow faster than the market?” The answer cannot be “because the market is growing.” The issuer must identify a specific growth driver that is unique to its business model.

Example from a successful 2024 HKEX Main Board listing (Company A, a BVI-incorporated healthcare services provider):

Market growth rate: 8.2% CAGR (2024-2029, source: Frost & Sullivan)
Company A’s growth rate: 24.7% CAGR (2024-2029, projected)
Growth driver: Expansion into 12 lower-tier cities where the company holds exclusive contracts with 34 county-level hospitals, a distribution model that competitors cannot replicate due to 5-year exclusive agreements.
Regulatory support: The company’s model aligns with the PRC’s “Healthy China 2030” policy, which provides tax incentives for healthcare providers in tier-3 and tier-4 cities.

The growth thesis must also address the “base effect” problem. A company growing at 50% on a HKD 50 million revenue base is not comparable to a company growing at 20% on a HKD 5 billion base. The prospectus should include a revenue bridge showing how growth rates will moderate over time, typically converging toward the market growth rate by year 5 post-IPO.

Pillar 2: The Defensible Market Position

Market position is not about being “the largest” or “the most innovative.” It is about demonstrating a structural advantage that prevents competitors from replicating the business model within a reasonable timeframe.

The four types of defensible positions that the HKEX Listing Committee has accepted in recent decisions (based on public listing documents from 2023-2025):

Regulatory moat: A Cayman-incorporated biotech company obtained a 10-year exclusive license from the PRC National Medical Products Administration (NMPA) for a Class III medical device. The regulatory approval process alone creates a 3-5 year barrier to entry for competitors.
Network effects: A Hong Kong-incorporated logistics platform connecting 12,000 delivery drivers with 45,000 merchants. The company’s data shows that each additional 1,000 merchants increases driver retention by 8.2%, creating a self-reinforcing cycle.
Cost advantage through scale: A BVI-incorporated manufacturing company with a 34% cost advantage over its nearest competitor, driven by a proprietary raw material sourcing agreement with a single PRC state-owned enterprise (SOE) that is not available to competitors.
Intellectual property: A Cayman-incorporated software company with 47 granted patents in the PRC, of which 12 are “invention patents” (the highest category under PRC patent law), creating a legal barrier to imitation.

The prospectus must include a competitor analysis table showing at least five direct competitors, with columns for revenue (last three fiscal years), gross margin, market share, and the specific barrier to entry that each competitor faces. The SFC has specifically requested this table in multiple RFIs in 2025.

Pillar 3: The Clear Path to Profitability

Under HKEX Rule 9.05(1), a Main Board applicant must satisfy either the profit test (minimum HKD 35 million profit in the most recent year and HKD 80 million aggregate over three years), the market cap/revenue test, or the market cap/revenue/cash flow test. However, the Exchange has increasingly focused on the “path to profitability” even for issuers applying under the non-profit tests.

Key metrics the Listing Committee examines:

Unit economics: The contribution margin per unit of product or service. For a SaaS company, this means LTV/CAC ratio, with a minimum acceptable ratio of 3:1 in most cases.
Operating leverage: The rate at which operating expenses (particularly S&M and G&A) decline as a percentage of revenue. A company that spends 60% of revenue on sales and marketing in year 1 must show that this ratio declines to below 30% by year 3.
Cash runway: A detailed cash flow forecast for 24 months post-listing, including the use of proceeds. The HKEX has returned applications where the use of proceeds section allocated less than 50% to revenue-generating activities.

The Differentiation Positioning: Avoiding the “Generic Trap”

The most common reason for a rejected or delayed listing application in 2024-2025 is the “generic trap”—a company that describes itself in terms that could apply to any competitor in its sector. The investment story must differentiate the company in a way that is both specific and verifiable.

The “Three-Sentence Test”

A Pre-IPO company’s investment story should pass the “three-sentence test”: an investor should be able to understand the company’s unique position in three sentences, without any jargon.

Example of a failed three-sentence test: “We are a leading technology-driven platform that leverages AI to provide comprehensive solutions to the healthcare industry. Our proprietary algorithms enable real-time data analytics and personalized patient engagement. We are disrupting the traditional healthcare model.”

Example of a passing three-sentence test: “We operate 34 exclusive hospital partnerships in lower-tier PRC cities that give us a 5-year head start on competitors in a market growing at 24% CAGR. Our proprietary inventory management system reduces hospital supply costs by 18%, a margin that competitors cannot match because our contracts are exclusive. We have achieved positive unit economics on 82% of our hospital contracts, and we project group-wide profitability by FY2027.”

The “Competitor Reference” Technique

One technique that has proven effective in recent HKEX listings is the “competitor reference” approach. Instead of claiming superiority, the company names its direct competitors and explains, with data, why each competitor cannot replicate its business model.

Example from a 2025 Main Board listing document (Company B, a BVI-incorporated education technology provider):

Competitor 1 (NYSE-listed): 3.2x larger revenue but operates only in tier-1 cities; cannot replicate Company B’s 1,200 school contracts in tier-3 cities because it has no local sales force.
Competitor 2 (A-share listed): 1.8x larger revenue but uses a different technology stack (offline vs. online); switching costs for schools are prohibitive.
Competitor 3 (private): 0.5x revenue but focused on K-12, not vocational training; no overlap in target market.

This approach satisfies the SFC’s requirement for “reasonable opinion” under paragraph 17.6(d) because it provides a verifiable, comparative analysis.

The Growth Narrative in a Cross-Border Context

For companies with a PRC operating entity and a Cayman or BVI holding company—the standard structure for a Hong Kong listing—the investment story must address the VIE (variable interest entity) risk explicitly. The SFC and HKEX have issued joint guidance (SFC/HKEX Joint Statement on VIE Structures, 2023) requiring issuers to disclose the specific regulatory risks associated with their VIE structure and to provide a “worst-case scenario” analysis of what happens if the VIE structure is invalidated.

VIE Risk Disclosure as Part of the Investment Story

The investment story cannot ignore the VIE risk; it must incorporate it as a risk factor that the company has mitigated. The standard mitigation strategies that the HKEX has accepted include:

A PRC law opinion from a qualified PRC law firm confirming that the VIE structure does not violate any current PRC regulations.
A contractual arrangement that includes a “call option” allowing the Cayman holding company to acquire the PRC operating entity’s equity if the VIE structure becomes illegal.
A disclosure that the company’s business is not in a “restricted” sector under the PRC Foreign Investment Negative List (2024 edition).

A 2024 listing document for a Cayman-incorporated fintech company included a 12-page appendix on VIE risk, including a scenario analysis showing the impact on revenue, profit, and market cap under three regulatory scenarios. This level of detail is now considered best practice.

Actionable Takeaways

Test your investment story against the “three-sentence test” — if an investor cannot understand your unique position in three sentences, the story is too generic and will not survive the HKEX’s Listing Committee scrutiny under LD143-2024.
Prepare a competitor matrix with at least five direct competitors — include revenue, gross margin, market share, and the specific barrier to entry for each competitor, as the SFC will request this under paragraph 17.6(d) of the Code of Conduct.
Quantify your growth thesis with a revenue bridge — show how growth rates will moderate over time, converging toward the market growth rate by year 5, and include sensitivity analysis under three macroeconomic scenarios.
Address the VIE risk explicitly in your investment story — include a PRC law opinion, a call option mechanism, and a scenario analysis showing the impact of regulatory changes, following the SFC/HKEX Joint Statement on VIE Structures (2023).
Allocate at least 50% of use of proceeds to revenue-generating activities — the HKEX has returned applications where the use of proceeds section was too vague or allocated too much to working capital, as this fails the “suitability for listing” test under HKEX Rule 9.11(23).